Entities / Company
KROS.
Slovak company
- Reports this week
- 0
- Active events
- 0
- Connections
- 21
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.Some support3 reports
-
KROS announced strategic realignment in Lexington on August 7, 2025.Some support1 report
-
The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.Some support1 report
-
ADAR1 Capital Management became the largest stockholder of KROS as of August 21, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Takeda Operational
The two companies are engaged in an ongoing global development partnership where Takeda leads the clinical trial milestones and payments.
History
Events by the month they beganJune 2026
4 events- Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.
- KROS announced strategic realignment in Lexington on August 7, 2025.
- The FDA granted Orphan Drug Designation for KER-065, a therapeutic being developed by KROS for DMD.
- ADAR1 Capital Management became the largest stockholder of KROS as of August 21, 2025.